Sarcoma
Conditions
Keywords
Leiomyosarcoma, Dedifferentiated liposarcoma, Myxoid liposarcoma, Synovialosarcoma, Osteosarcoma, Ewing's sarcoma, Cancer cell/macrophage hybrid cells, Hybrid cells
Brief summary
Pilot, prospective, monocentric study aimed at evaluating the rate of patients with circulating cancer cell/macrophage hybrid cells in the peripheral blood. The study will be conducted on a population of patients with sarcoma and treated in the context of routine care. For each included patient, blood samples will be collected during baseline visit and after the initiation therapy. At the end of the 2nd blood collection, the patient will have completed his participation in the study.
Interventions
OTHERBlood samples will be collected at two times :
* at Baseline, * after surgery or at the time of post-chemotherapy evaluation.
Sponsors
Institut Claudius Regaud
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Patient with one of the following subtypes of soft tissue or bone sarcomas: leiomyosarcoma, dedifferentiated liposarcoma, myxoid liposarcoma, synovialosarcoma, osteosarcoma, Ewing's sarcoma. 2. Diagnosis of sarcoma histologically confirmed by the RRePS network (Réseau de Référence en Pathologie des Sarcomes et des Viscères) 3. Age ≥ 18 years old. 4. Localized or metastatic disease or recurrent disease. 5. Patient who has not yet initiated specific treatment for sarcoma. 6. Patient affiliated to a Social Health Insurance in France. 7. Patient having signed informed consent prior to inclusion in the study and prior to any specific study procedures.
Exclusion criteria
1. Patient with any other histological subtype of sarcoma, including pleomorphic sarcoma. 2. Associated pathology(s) that may prevent the proper conduct of the procedure under consideration. 3. Pregnant or breastfeeding woman. 4. Any psychological, family, geographical or sociological condition that prevents compliance with the medical follow-up and/or procedures of the study protocol. 5. Patient who has forfeited his/her freedom by administrative or legal award or who is under legal protection (curatorship and guardianship, protection of justice).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Rate of patients with cancer cell / macrophage hybrid cells in peripheral blood. | 6 months after the end of inclusions |
Secondary
| Measure | Time frame |
|---|---|
| Quantification of circulating hybrid cells in peripheral blood by automatic measurement (Cell Counter Corning) and expressed in number of cells / millilitre of blood. | 6 months after the end of inclusions |
Countries
France
Outcome results
None listed